Improve The Treatment Of PTSD Can Be Through The Amygdala.
Researchers who have deliberate a piece with a missing amygdala - the part of the brain believed to form fear - report that their findings may help improve treatment for post-traumatic ictus disorder (PTSD) and other anxiety disorders. In perhaps the first human study confirming that the almond-shaped build is crucial for triggering fear, researchers at the University of Iowa monitored a 44-year-old woman's comeback to typically frightening stimuli such as snakes, spiders, horror films and a haunted house, and asked about upsetting experiences in her past. The woman, identified as SM, does not seem to anxiety a wide range of stimuli that would normally frighten most people.
Scientists have been studying her for the past 20 years, and their previous research had already determined that the woman cannot recognize fear in others' facial expressions. SM suffers from an hellishly rare disease that destroyed her amygdala. Future observations will determine if her adapt affects anxiety levels for everyday stressors such as finance or health issues, said scrutiny author Justin Feinstein, a University of Iowa doctoral student studying clinical neuropsychology. "Certainly, when it comes to fear, she's missing it," Feinstein said. "She's so single in her presentation".
Researchers said the study, reported in the Dec 16, 2010 outflow of the journal Current Biology, could advanced position to new treatment strategies for PTSD and anxiety disorders. According to the US National Institute of Mental Health, more than 7,7 million Americans are mannered by the condition, and a 2008 division predicted that 300000 soldiers returning from combat in the Middle East would experience PTSD. "Because of her cognition damage, the patient appears to be immune to PTSD," Feinstein said, noting that she is otherwise cognitively normal and experiences other emotions such as happiness and sadness.
In addition to recording her responses to spiders, snakes and other unnerving stimuli, the researchers measured her experience of fear using many standardized questionnaires that probed various aspects of the emotion, such as respect of death or fear of public speaking. She also carried a computerized sensation diary for three months that randomly asked her to rate her fear level throughout the day.
Friday 28 February 2014
Thursday 27 February 2014
Surgeons Found The Role Of Obesity In Cancer
Surgeons Found The Role Of Obesity In Cancer.
Obesity and smoking growth the imperil of implant failure in women who undergo breast reconstruction soon after chest removal, according to a new study. Researchers analyzed data from nearly 15000 women, aged 40 to 60, who had reflex reconstruction after breast removal (mastectomy). They found that the risk of implant failure was three times higher in smokers and two to three times higher in obese women. The more heavy a woman, the greater her risk of early implant failure, according to the study, which was published in the December spring of the Journal of the American College of Surgeons.
Other factors associated with a higher peril of implant loss included being older than 55, receiving implants in both breasts, and undergoing both boob removal and reconstruction with implants in a single operation. "Less than 1 percent of all patients in our chew over experienced implant failure ," study lead author Dr John Fischer, a inexperienced surgery resident at the Perelman School of Medicine at the University of Pennsylvania, said in a dossier news release.
Obesity and smoking growth the imperil of implant failure in women who undergo breast reconstruction soon after chest removal, according to a new study. Researchers analyzed data from nearly 15000 women, aged 40 to 60, who had reflex reconstruction after breast removal (mastectomy). They found that the risk of implant failure was three times higher in smokers and two to three times higher in obese women. The more heavy a woman, the greater her risk of early implant failure, according to the study, which was published in the December spring of the Journal of the American College of Surgeons.
Other factors associated with a higher peril of implant loss included being older than 55, receiving implants in both breasts, and undergoing both boob removal and reconstruction with implants in a single operation. "Less than 1 percent of all patients in our chew over experienced implant failure ," study lead author Dr John Fischer, a inexperienced surgery resident at the Perelman School of Medicine at the University of Pennsylvania, said in a dossier news release.
Development Of Tablets To Reduce The Desire For High-Calorie Food
Development Of Tablets To Reduce The Desire For High-Calorie Food.
You're dieting, and you positive you should retard away from high-calorie snacks. Yet, your eyes muzzle straying toward that box of chocolates, and you wish there was a pill to restrain your impulse to inhale them. Such a capsule might one day be a real possibility, according to findings presented Tuesday at the Endocrine Society's annual assignation in San Diego. It would block the activity of ghrelin, the "hunger hormone" that stimulates the passion centers of the brain.
The study, reported by Dr Tony Goldstone, a consultant endocrinologist at the British Medical Research Council Clinical Sciences Center at Imperial College London, showed that ghrelin does mother the hanker after for high-calorie foods in humans. "It's been known from animal and beneficent work that ghrelin makes people hungrier," Goldstone said. "There has been a suspicion from mammal work that it can also stimulate the rewards pathways of the brain and may be involved in the response to more rewarding foods, but we didn't have indication of that in people".
The study that provided such evidence had 18 healthy adults look at pictures of unlike foods on three mornings, once after skipping breakfast and twice about 90 minutes after having breakfast. On one of the breakfast-eating mornings, all the participants got injections - some of soused water, some of ghrelin. Then they looked at pictures of high-calorie foods such as chocolate, bar and pizza, and low-calorie foods such as salads and vegetables.
The participants in use a keyboard to rate the appeal of those pictures. Low-calorie foods were rated about the same, no purport what was in the injections. But the high-calorie foods, especially sweets, rated higher in those who got ghrelin. "It seems to vary the desire for high-calorie foods more than low-calorie foods," Goldstone said of ghrelin.
You're dieting, and you positive you should retard away from high-calorie snacks. Yet, your eyes muzzle straying toward that box of chocolates, and you wish there was a pill to restrain your impulse to inhale them. Such a capsule might one day be a real possibility, according to findings presented Tuesday at the Endocrine Society's annual assignation in San Diego. It would block the activity of ghrelin, the "hunger hormone" that stimulates the passion centers of the brain.
The study, reported by Dr Tony Goldstone, a consultant endocrinologist at the British Medical Research Council Clinical Sciences Center at Imperial College London, showed that ghrelin does mother the hanker after for high-calorie foods in humans. "It's been known from animal and beneficent work that ghrelin makes people hungrier," Goldstone said. "There has been a suspicion from mammal work that it can also stimulate the rewards pathways of the brain and may be involved in the response to more rewarding foods, but we didn't have indication of that in people".
The study that provided such evidence had 18 healthy adults look at pictures of unlike foods on three mornings, once after skipping breakfast and twice about 90 minutes after having breakfast. On one of the breakfast-eating mornings, all the participants got injections - some of soused water, some of ghrelin. Then they looked at pictures of high-calorie foods such as chocolate, bar and pizza, and low-calorie foods such as salads and vegetables.
The participants in use a keyboard to rate the appeal of those pictures. Low-calorie foods were rated about the same, no purport what was in the injections. But the high-calorie foods, especially sweets, rated higher in those who got ghrelin. "It seems to vary the desire for high-calorie foods more than low-calorie foods," Goldstone said of ghrelin.
Monday 24 February 2014
Controversial Guidelines Of Treatment Of Lyme Disease Is Left In Action
Controversial Guidelines Of Treatment Of Lyme Disease Is Left In Action.
After more than a year of study, a expressly appointed panel at the Infectious Diseases Society of America has unquestionable that argumentative guidelines for the treatment of Lyme disease are correct and have occasion for not be changed. The guidelines, first adopted in 2006, have long advocated for the short-term (less than a month) antibiotic curing of new infections of Lyme disease, which is caused by Borrelia burgdorferi, a bacteria transmitted to humans via tick bites.
However, the guidelines have also been the cynosure of fierce antipathy from certain patient advocate groups that believe there is a debilitating, "chronic" form of Lyme affliction requiring much longer therapy. The IDSA guidelines are important because doctors and insurance companies often follow them when making care (and treatment reimbursement) decisions.
The new review was sparked by an review launched by Connecticut Attorney General Richard Blumenthal, whose office had concerns about the process cast-off to draft the guidelines. "This was the first challenge to any of the infectious disease guidelines" the Society has issued over the years, IDSA president Dr Richard Whitley said during a host conference held Thursday.
Whitley eminent that the special panel was put together with an independent medical ethicist, Dr Howard Brody, from the University of Texas Medical Branch, who was approved by Blumenthal so that the body would be sure to have no conflicts of interest. The guidelines check 69 recommendations, Dr Carol J Baker, stool of the Review Panel, and pediatric infectious diseases specialist at Baylor College of Medicine, said during the cluster conference.
So "For each of these recommendations our review panel found that each was medically and scientifically justified in torch of all the evidence and information and required no revision," she said. For all but one of the votes the committee agreed unanimously, Baker added.
Particularly on the continued use of antibiotics, the panel had concerns that prolonged use of these drugs puts patients in threat of precarious infection while not improving their condition, Baker said. "In the case of Lyme disease, there has yet to be a unique high-quality clinical study that demonstrates comparable benefit to prolonging antibiotic treatment beyond one month," the panel members found.
After more than a year of study, a expressly appointed panel at the Infectious Diseases Society of America has unquestionable that argumentative guidelines for the treatment of Lyme disease are correct and have occasion for not be changed. The guidelines, first adopted in 2006, have long advocated for the short-term (less than a month) antibiotic curing of new infections of Lyme disease, which is caused by Borrelia burgdorferi, a bacteria transmitted to humans via tick bites.
However, the guidelines have also been the cynosure of fierce antipathy from certain patient advocate groups that believe there is a debilitating, "chronic" form of Lyme affliction requiring much longer therapy. The IDSA guidelines are important because doctors and insurance companies often follow them when making care (and treatment reimbursement) decisions.
The new review was sparked by an review launched by Connecticut Attorney General Richard Blumenthal, whose office had concerns about the process cast-off to draft the guidelines. "This was the first challenge to any of the infectious disease guidelines" the Society has issued over the years, IDSA president Dr Richard Whitley said during a host conference held Thursday.
Whitley eminent that the special panel was put together with an independent medical ethicist, Dr Howard Brody, from the University of Texas Medical Branch, who was approved by Blumenthal so that the body would be sure to have no conflicts of interest. The guidelines check 69 recommendations, Dr Carol J Baker, stool of the Review Panel, and pediatric infectious diseases specialist at Baylor College of Medicine, said during the cluster conference.
So "For each of these recommendations our review panel found that each was medically and scientifically justified in torch of all the evidence and information and required no revision," she said. For all but one of the votes the committee agreed unanimously, Baker added.
Particularly on the continued use of antibiotics, the panel had concerns that prolonged use of these drugs puts patients in threat of precarious infection while not improving their condition, Baker said. "In the case of Lyme disease, there has yet to be a unique high-quality clinical study that demonstrates comparable benefit to prolonging antibiotic treatment beyond one month," the panel members found.
Monday 17 February 2014
Sulfonylurea Drugs Increase The Risk Of Heart Disease
Sulfonylurea Drugs Increase The Risk Of Heart Disease.
New experiment with shows that older ladies and gentlemen with type 2 diabetes who take drugs known as sulfonylureas to humble their blood sugar levels may face a higher risk for heart problems than their counterparts who induce metformin. Of the more than 8500 people aged 65 or older with breed 2 diabetes who were enrolled in the trial, 12,4 percent of those given a sulfonylurea drug experienced a middle attack or other cardiovascular event, compared with 10,4 percent of those who were started on metformin. In addition, these heartlessness problems occurred earlier in the course of treatment among those people taking the sulfonylurea drugs, the lessons showed.
The head-to-head comparison trial is slated to be presented Saturday at the American Diabetes Association annual tryst in San Diego. Because the findings are being reported at a medical meeting, they should be considered preparation until published in a peer-reviewed journal. With type 2 diabetes, the body either does not spark enough of the hormone insulin or doesn't use the insulin it does produce properly.
In either case, the insulin can't do its job, which is to throw glucose (blood sugar) to the body's cells. As a result, glucose builds up in the blood and can impose havoc on the body. Metformin and sulfonylurea drugs - the latter a stock of diabetes drugs including glyburide, glipizide, chlorpropamide, tolbutamide and tolazamide - are often among the first medications prescribed to lower blood sugar levels in people with type 2 diabetes.
The findings are important, the researchers noted, partly because sulfonylurea drugs are commonly prescribed middle the senile to lower blood glucose levels. In addition, cardiovascular sickness is the leading cause of death among people with type 2 diabetes. For several reasons, however, the strange study on these medications is far from the final word on the issue, experts said.
For one, men and women who are started on the sulfonylureas instead of metformin are often sicker to begin with, said Dr Spyros G Mezitis, an endocrinologist at Lenox Hill Hospital in New York City. Metformin cannot be prescribed to kinfolk with firm kidney and heart problems, he said. Both medications lower blood glucose levels, but go about it in clearly different ways, he explained.
New experiment with shows that older ladies and gentlemen with type 2 diabetes who take drugs known as sulfonylureas to humble their blood sugar levels may face a higher risk for heart problems than their counterparts who induce metformin. Of the more than 8500 people aged 65 or older with breed 2 diabetes who were enrolled in the trial, 12,4 percent of those given a sulfonylurea drug experienced a middle attack or other cardiovascular event, compared with 10,4 percent of those who were started on metformin. In addition, these heartlessness problems occurred earlier in the course of treatment among those people taking the sulfonylurea drugs, the lessons showed.
The head-to-head comparison trial is slated to be presented Saturday at the American Diabetes Association annual tryst in San Diego. Because the findings are being reported at a medical meeting, they should be considered preparation until published in a peer-reviewed journal. With type 2 diabetes, the body either does not spark enough of the hormone insulin or doesn't use the insulin it does produce properly.
In either case, the insulin can't do its job, which is to throw glucose (blood sugar) to the body's cells. As a result, glucose builds up in the blood and can impose havoc on the body. Metformin and sulfonylurea drugs - the latter a stock of diabetes drugs including glyburide, glipizide, chlorpropamide, tolbutamide and tolazamide - are often among the first medications prescribed to lower blood sugar levels in people with type 2 diabetes.
The findings are important, the researchers noted, partly because sulfonylurea drugs are commonly prescribed middle the senile to lower blood glucose levels. In addition, cardiovascular sickness is the leading cause of death among people with type 2 diabetes. For several reasons, however, the strange study on these medications is far from the final word on the issue, experts said.
For one, men and women who are started on the sulfonylureas instead of metformin are often sicker to begin with, said Dr Spyros G Mezitis, an endocrinologist at Lenox Hill Hospital in New York City. Metformin cannot be prescribed to kinfolk with firm kidney and heart problems, he said. Both medications lower blood glucose levels, but go about it in clearly different ways, he explained.
Thursday 13 February 2014
A New Drug For The Treatment Of Skin Cancer Increases The Survival Of Patients
A New Drug For The Treatment Of Skin Cancer Increases The Survival Of Patients.
Scientists give the word that a imaginative drug to bonus melanoma, the first in its class, improved survival by 68 percent in patients whose disease had blanket from the skin to other parts of the body. This is big news in the field of melanoma research, where survival rates have refused to budge, in spite of numerous efforts to come up with an effective treatment for the increasingly common and harmful skin cancer over the past three decades. "The last time a drug was approved for metastatic melanoma was 12 years ago, and 85 percent of woman in the street who take that slip have no benefit, so finding another drug that is going to have an impact, and even a bigger impact than what's out there now, is a vital improvement for patients," said Timothy Turnham, executive director of the Melanoma Research Foundation in Washington, DC.
The findings on the drug, called ipilimumab, were reported simultaneously Saturday at the annual engagement of the American Society of Clinical Oncology (ASCO) in Chicago and in the June 5 online young of the New England Journal of Medicine. Ipilimumab is the principal in a new class of targeted T-cell antibodies, with possibility applications for other cancers as well.
Both the incidence of metastatic melanoma and the eradication rate have risen during the past 30 years, and patients with advanced disease typically have small treatment options. "Ipilimumab is a human monoclonal antibody directed against CTLA-4, which is on the surface of T-cells which fray infection ," explained lead study author Dr Steven O'Day, top dog of the melanoma program at the Angeles Clinic and Research Institute in Los Angeles. "CTL is a very notable break to the immune system, so by blocking this break with ipilimumab, it accelerates and potentiates the T-cells. And by doing that they become activated and can go out and use up the cancer.
Scientists give the word that a imaginative drug to bonus melanoma, the first in its class, improved survival by 68 percent in patients whose disease had blanket from the skin to other parts of the body. This is big news in the field of melanoma research, where survival rates have refused to budge, in spite of numerous efforts to come up with an effective treatment for the increasingly common and harmful skin cancer over the past three decades. "The last time a drug was approved for metastatic melanoma was 12 years ago, and 85 percent of woman in the street who take that slip have no benefit, so finding another drug that is going to have an impact, and even a bigger impact than what's out there now, is a vital improvement for patients," said Timothy Turnham, executive director of the Melanoma Research Foundation in Washington, DC.
The findings on the drug, called ipilimumab, were reported simultaneously Saturday at the annual engagement of the American Society of Clinical Oncology (ASCO) in Chicago and in the June 5 online young of the New England Journal of Medicine. Ipilimumab is the principal in a new class of targeted T-cell antibodies, with possibility applications for other cancers as well.
Both the incidence of metastatic melanoma and the eradication rate have risen during the past 30 years, and patients with advanced disease typically have small treatment options. "Ipilimumab is a human monoclonal antibody directed against CTLA-4, which is on the surface of T-cells which fray infection ," explained lead study author Dr Steven O'Day, top dog of the melanoma program at the Angeles Clinic and Research Institute in Los Angeles. "CTL is a very notable break to the immune system, so by blocking this break with ipilimumab, it accelerates and potentiates the T-cells. And by doing that they become activated and can go out and use up the cancer.
Tuesday 11 February 2014
New Incidence Of STDs In The United States
New Incidence Of STDs In The United States.
The approximately 19 million redone sexually transmitted blight (STD) infections that occur each year in the United States sell for the health care system about $16,4 billion annually, the US Centers for Disease Control and Prevention said in its annual STD news released Monday. The evidence for 2009 shows a continued high burden of STDs but there are some signs of progress, according to the report, which focuses on chlamydia, gonorrhea and syphilis. The federal rate of reported gonorrhea cases stands at 99 cases per 100000 people, its lowest devastate since make a notation keeping started in 1941, and cases are declining among all racial/ethnic groups (down 17 percent since 2006).
Since 2006, chlamydia infections have increased 19 percent to about 409 per 100000 people. However, the announce suggests that this indicates more commonality than ever are being screened for chlamydia, which is one of the most undistinguished STDs in the United States.
The approximately 19 million redone sexually transmitted blight (STD) infections that occur each year in the United States sell for the health care system about $16,4 billion annually, the US Centers for Disease Control and Prevention said in its annual STD news released Monday. The evidence for 2009 shows a continued high burden of STDs but there are some signs of progress, according to the report, which focuses on chlamydia, gonorrhea and syphilis. The federal rate of reported gonorrhea cases stands at 99 cases per 100000 people, its lowest devastate since make a notation keeping started in 1941, and cases are declining among all racial/ethnic groups (down 17 percent since 2006).
Since 2006, chlamydia infections have increased 19 percent to about 409 per 100000 people. However, the announce suggests that this indicates more commonality than ever are being screened for chlamydia, which is one of the most undistinguished STDs in the United States.
Friday 7 February 2014
People With Diabetes May Have An Increased Risk Of Cancer
People With Diabetes May Have An Increased Risk Of Cancer.
People with diabetes may have something else to be vexed about - an increased gamble of cancer, according to a redone consensus report produced by experts recruited jointly by the American Cancer Society and the American Diabetes Association. Diabetes, pre-eminently type 2 diabetes, has been linked to certain cancers, though experts aren't established if the disease itself leads to the increased risk or if shared risk factors, such as obesity, may be to blame. Other delve into has suggested that some diabetes treatments, such as certain insulins, may also be associated with the maturity of some cancers.
But the evidence isn't conclusive, and it's difficult to tease out whether the insulin is directorial for the association or other risk factors associated with diabetes could be the root of the link. "There have been some epidemiological studies that suggest that individuals who are stout or who have high levels of insulin appear to have an increased prevalence of certain malignancies, but it's a complex go forth because the association is not true for all cancers," explained Dr David Harlan, pilot of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester, and one of the authors of the consensus report. "So, there's some smoke to suggest an society - but no clear fire," he added.
As for the imaginable insulin-and-cancer link, Harlan said that because a weak association was found, it's plainly an area that needs to be pursued further. But, he said, that doesn't mean that anyone should change the velocity they're managing their diabetes. "Our greatest concern is that individuals with diabetes might choose not to care for their diabetes with insulin or a particular insulin out of concern for a malignancy.
The risk of diabetes complications is a far greater concern," prominent Harlan. "It's like when someone decides to drive across the mother country because they're afraid to fly. While there is a slight risk of dying in a plane crash, statistically it's far riskier to drive". The consensus despatch is published in the July/August issue of CA: A Cancer Journal for Clinicians.
People with diabetes may have something else to be vexed about - an increased gamble of cancer, according to a redone consensus report produced by experts recruited jointly by the American Cancer Society and the American Diabetes Association. Diabetes, pre-eminently type 2 diabetes, has been linked to certain cancers, though experts aren't established if the disease itself leads to the increased risk or if shared risk factors, such as obesity, may be to blame. Other delve into has suggested that some diabetes treatments, such as certain insulins, may also be associated with the maturity of some cancers.
But the evidence isn't conclusive, and it's difficult to tease out whether the insulin is directorial for the association or other risk factors associated with diabetes could be the root of the link. "There have been some epidemiological studies that suggest that individuals who are stout or who have high levels of insulin appear to have an increased prevalence of certain malignancies, but it's a complex go forth because the association is not true for all cancers," explained Dr David Harlan, pilot of the Diabetes Center of Excellence at the University of Massachusetts Memorial Medical Center in Worcester, and one of the authors of the consensus report. "So, there's some smoke to suggest an society - but no clear fire," he added.
As for the imaginable insulin-and-cancer link, Harlan said that because a weak association was found, it's plainly an area that needs to be pursued further. But, he said, that doesn't mean that anyone should change the velocity they're managing their diabetes. "Our greatest concern is that individuals with diabetes might choose not to care for their diabetes with insulin or a particular insulin out of concern for a malignancy.
The risk of diabetes complications is a far greater concern," prominent Harlan. "It's like when someone decides to drive across the mother country because they're afraid to fly. While there is a slight risk of dying in a plane crash, statistically it's far riskier to drive". The consensus despatch is published in the July/August issue of CA: A Cancer Journal for Clinicians.
The Human Brain Reacts Differently To The Use Of Fructose And Glucose
The Human Brain Reacts Differently To The Use Of Fructose And Glucose.
New fact-finding suggests that fructose, a righteous sugar found clearly in fruit and added to many other foods as part of high-fructose corn syrup, does not dampen appetite and may cause kinfolk to eat more compared to another simple sugar, glucose. Glucose and fructose are both simple sugars that are included in regular parts in table sugar. In the new study, brain scans suggest that distinct things happen in your brain, depending on which sugar you consume.
Yale University researchers looked for appetite-related changes in blood gurgle in the hypothalamic region of the brains of 20 healthy adults after they ate either glucose or fructose. When population consumed glucose, levels of hormones that play a role in identification full were high. In contrast, when participants consumed a fructose beverage, they showed smaller increases in hormones that are associated with overindulgence (feeling full).
The findings are published in the Jan 2, 2013 emerge of the Journal of the American Medical Association. Dr Jonathan Purnell, of Oregon Health & Science University in Portland, co-authored an op-ed article that accompanied the new study. He said that the findings replicate those found in previous animal studies, but "this does not prove that fructose is the cause of the grossness epidemic, only that it is a possible contributor along with many other environmental and genetic factors".
That said, fructose has found its way into Americans' diets in the produce of sugars - typically in the form of high-fructose corn syrup - that are added to beverages and processed foods. "This increased intake of added sugar containing fructose over the existence several decades has coincided with the be created in obesity in the population, and there is strong evidence from coarse studies that this increased intake of fructose is playing a role in this phenomenon," said Purnell, who is buddy professor in the university's division of endocrinology, diabetes and clinical nutrition.
But he stressed that nutritionists do not "recommend avoiding bastard sources of fructose, such as fruit, or the occasional use of honey or syrup". And according to Purnell, "excess consumption of processed sugar can be minimized by preparing meals at severely using whole foods and high-fiber grains".
New fact-finding suggests that fructose, a righteous sugar found clearly in fruit and added to many other foods as part of high-fructose corn syrup, does not dampen appetite and may cause kinfolk to eat more compared to another simple sugar, glucose. Glucose and fructose are both simple sugars that are included in regular parts in table sugar. In the new study, brain scans suggest that distinct things happen in your brain, depending on which sugar you consume.
Yale University researchers looked for appetite-related changes in blood gurgle in the hypothalamic region of the brains of 20 healthy adults after they ate either glucose or fructose. When population consumed glucose, levels of hormones that play a role in identification full were high. In contrast, when participants consumed a fructose beverage, they showed smaller increases in hormones that are associated with overindulgence (feeling full).
The findings are published in the Jan 2, 2013 emerge of the Journal of the American Medical Association. Dr Jonathan Purnell, of Oregon Health & Science University in Portland, co-authored an op-ed article that accompanied the new study. He said that the findings replicate those found in previous animal studies, but "this does not prove that fructose is the cause of the grossness epidemic, only that it is a possible contributor along with many other environmental and genetic factors".
That said, fructose has found its way into Americans' diets in the produce of sugars - typically in the form of high-fructose corn syrup - that are added to beverages and processed foods. "This increased intake of added sugar containing fructose over the existence several decades has coincided with the be created in obesity in the population, and there is strong evidence from coarse studies that this increased intake of fructose is playing a role in this phenomenon," said Purnell, who is buddy professor in the university's division of endocrinology, diabetes and clinical nutrition.
But he stressed that nutritionists do not "recommend avoiding bastard sources of fructose, such as fruit, or the occasional use of honey or syrup". And according to Purnell, "excess consumption of processed sugar can be minimized by preparing meals at severely using whole foods and high-fiber grains".
Tuesday 4 February 2014
Human Growth Hormone (HGH) Enhances Athletic Performance Like Testosterone
Human Growth Hormone (HGH) Enhances Athletic Performance Like Testosterone.
Human excrescence hormone, a corporeality frequently implicated in sports doping scandals, does seem to encourage athletic performance, a new study shows. Australian researchers gave 96 non-professional athletes venerable 18 to 40 injections of either HGH or a saline placebo. Participants included 63 men and 33 women. About half of the virile participants also received a second injection of testosterone or placebo.
After eight weeks, men and women given HGH injections sprinted faster on a bicycle and had reduced heaviness load and more lean body mass. Adding in testosterone boosted those crap - in men also given testosterone, the impact on sprinting ability was nearly doubled. HGH, however, had no consequence on jumping ability, aerobic capacity or strength, measured by the ability to dead-lift a weight, nor did HGH multiply muscle mass.
So "This paper adds to the scientific evidence that HGH can be play enhancing, and from our perspective at World Anti-Doping Agency (WADA), lends support to bans on HGH," said Olivier Rabin, WADA's branch director. The study, which was funded in area by WADA, is in the May 4 issue of the Annals of Internal Medicine. Human growth hormone is amongst the substances banned by the WADA for use by competitive athletes.
HGH is also banned by Major League Baseball, though the federation doesn't currently test for it. HGH has made headlines in the sports world. Recently, American tennis entertainer Wayne Odesnik accepted a voluntary suspension for importing the sum total into Australia, while Tiger Woods denied using it after the assistant to a prominent sports medicine adroit who had treated Woods was arrested at the US-Canada border with HGH.
However, based on anecdotal reports and athlete testimonies, HGH is to a large abused in professional sports, said Mark Frankel, manager of the scientific freedom, responsibility and law program for the American Association for the Advancement of Science. Prior into or has suggested HGH reduces fat mass, Rabin said, as well as help the body bring back more quickly from injury or "microtraumas" - small injuries to the muscles, bones or joints that befall as a result of intense training. That type of a boost could put athletes at a competitive advantage, Rabin said.
Human excrescence hormone, a corporeality frequently implicated in sports doping scandals, does seem to encourage athletic performance, a new study shows. Australian researchers gave 96 non-professional athletes venerable 18 to 40 injections of either HGH or a saline placebo. Participants included 63 men and 33 women. About half of the virile participants also received a second injection of testosterone or placebo.
After eight weeks, men and women given HGH injections sprinted faster on a bicycle and had reduced heaviness load and more lean body mass. Adding in testosterone boosted those crap - in men also given testosterone, the impact on sprinting ability was nearly doubled. HGH, however, had no consequence on jumping ability, aerobic capacity or strength, measured by the ability to dead-lift a weight, nor did HGH multiply muscle mass.
So "This paper adds to the scientific evidence that HGH can be play enhancing, and from our perspective at World Anti-Doping Agency (WADA), lends support to bans on HGH," said Olivier Rabin, WADA's branch director. The study, which was funded in area by WADA, is in the May 4 issue of the Annals of Internal Medicine. Human growth hormone is amongst the substances banned by the WADA for use by competitive athletes.
HGH is also banned by Major League Baseball, though the federation doesn't currently test for it. HGH has made headlines in the sports world. Recently, American tennis entertainer Wayne Odesnik accepted a voluntary suspension for importing the sum total into Australia, while Tiger Woods denied using it after the assistant to a prominent sports medicine adroit who had treated Woods was arrested at the US-Canada border with HGH.
However, based on anecdotal reports and athlete testimonies, HGH is to a large abused in professional sports, said Mark Frankel, manager of the scientific freedom, responsibility and law program for the American Association for the Advancement of Science. Prior into or has suggested HGH reduces fat mass, Rabin said, as well as help the body bring back more quickly from injury or "microtraumas" - small injuries to the muscles, bones or joints that befall as a result of intense training. That type of a boost could put athletes at a competitive advantage, Rabin said.
Sunday 2 February 2014
The Wounded Soldier Was Saved From The Acquisition Of Diabetes Through An Emergency Transplantation Of Cells
The Wounded Soldier Was Saved From The Acquisition Of Diabetes Through An Emergency Transplantation Of Cells.
In the word go control of its kind, a wounded Tommy whose damaged pancreas had to be removed was able to have his own insulin-producing islet cells transplanted back into him, prudent him from a life with the most severe form of type 1 diabetes. In November 2009, 21-year-old Senior Airman Tre Porfirio was serving in a implausible scope of Afghanistan when an insurgent who had been pretending to be a soldier in the Afghan army shot him three times at palsy-walsy range with a high-velocity rifle.
After undergoing two surgeries in the field to stop the bleeding, Porfirio was transferred to the Walter Reed Army Medical Center in Washington, DC As area of the surgery in the field, a parcel of Porfirio's stomach, the gallbladder, the duodenum, and a section of his pancreas had been removed. At Walter Reed, surgeons expected that they would be reconstructing the structures in the abdomen that had been damaged.
However, they with dispatch discovered that the unused portion of the pancreas was leaking pancreatic enzymes that were dissolving parts of other organs and blood vessels, according to their blast in the April 22 issue of the New England Journal of Medicine. "When I went into surgery with Tre, my ambition was to reconnect everything, but I discovered a very dire, treacherous situation," said Dr Craig Shriver, Walter Reed's chief of run-of-the-mill surgery.
So "I knew I would now have to remove the remainder of his pancreas, but I also knew that leads to a life-threatening propriety of diabetes. The pancreas makes insulin and glucagon, which take out the extremes of very consequential and very low blood sugar," Shriver explained. Because he didn't want to leave this serve with this life-threatening condition, Shriver consulted with his Walter Reed colleague, transplant surgeon Dr Rahul Jindal.
Jindal said that Porfirio could greet a pancreas transplant from a matched donor at a later date, but that would ask lifelong use of immune-suppressing medications. Another option, Jindal said, was a relocate using Porfirio's own islet cells - cells within the pancreas that produce insulin and glucagon. The conduct is known as autologous islet cell transplantion.
In the word go control of its kind, a wounded Tommy whose damaged pancreas had to be removed was able to have his own insulin-producing islet cells transplanted back into him, prudent him from a life with the most severe form of type 1 diabetes. In November 2009, 21-year-old Senior Airman Tre Porfirio was serving in a implausible scope of Afghanistan when an insurgent who had been pretending to be a soldier in the Afghan army shot him three times at palsy-walsy range with a high-velocity rifle.
After undergoing two surgeries in the field to stop the bleeding, Porfirio was transferred to the Walter Reed Army Medical Center in Washington, DC As area of the surgery in the field, a parcel of Porfirio's stomach, the gallbladder, the duodenum, and a section of his pancreas had been removed. At Walter Reed, surgeons expected that they would be reconstructing the structures in the abdomen that had been damaged.
However, they with dispatch discovered that the unused portion of the pancreas was leaking pancreatic enzymes that were dissolving parts of other organs and blood vessels, according to their blast in the April 22 issue of the New England Journal of Medicine. "When I went into surgery with Tre, my ambition was to reconnect everything, but I discovered a very dire, treacherous situation," said Dr Craig Shriver, Walter Reed's chief of run-of-the-mill surgery.
So "I knew I would now have to remove the remainder of his pancreas, but I also knew that leads to a life-threatening propriety of diabetes. The pancreas makes insulin and glucagon, which take out the extremes of very consequential and very low blood sugar," Shriver explained. Because he didn't want to leave this serve with this life-threatening condition, Shriver consulted with his Walter Reed colleague, transplant surgeon Dr Rahul Jindal.
Jindal said that Porfirio could greet a pancreas transplant from a matched donor at a later date, but that would ask lifelong use of immune-suppressing medications. Another option, Jindal said, was a relocate using Porfirio's own islet cells - cells within the pancreas that produce insulin and glucagon. The conduct is known as autologous islet cell transplantion.
Saturday 1 February 2014
New Ways Of Treating Prostate Cancer And Ovarian Cancer
New Ways Of Treating Prostate Cancer And Ovarian Cancer.
New investigate supports creative ways to treat ovarian and prostate cancer, while producing a mortification for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could interchange clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the affliction in its advanced stages and more men getting radiation therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual meet in Chicago. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating undoubted colon cancer patients, found the antidepressant made little difference to their survival.
The first swot found that adding Avastin to standard chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo as a matter of fact slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, gist it interferes with a tumor's blood supply. "This is the first molecular-targeted and opening anti-angiogenesis therapy to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one law option for women with this disease," said lead researcher Dr Robert A Burger, governor of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.
So "This is a unusual potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending medical doctor at Northshore University Health System and arbiter of a Sunday news conference at which these results were presented. The phase 3 think over involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received canon chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their complaint progressing compared with about 10 months for those receiving example chemotherapy alone.
Those who received chemo plus Avastin but no maintenance drug lived without a recurrence for 11,3 months, a diversity not considered statistically significant. "I'm cautiously optimistic about this data. It utterly shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I ruminate we have to heels for longer term outcomes before we make particular conclusions. It's too early for overall survival benefit data".
However, he pointed out, a four-month conversion for progression-free survival is "substantial". Doctors are already using Avastin off-label widely to treat ovarian cancer, he said, although it is not yet approved for this use. It has been shown to be more effective in this cancer than in many cancers for which it is approved, Morgan noted.
New investigate supports creative ways to treat ovarian and prostate cancer, while producing a mortification for those with a certain form of colon cancer. Both the ovarian and prostate cancer trials could interchange clinical practice, with more women taking the drug bevacizumab (Avastin) to combat the affliction in its advanced stages and more men getting radiation therapy for locally advanced prostate cancer, according to researchers who presented the findings Sunday at the American Society of Clinical Oncology (ASCO) annual meet in Chicago. A third trial, looking at the effectiveness of cetuximab (Erbitux) in treating undoubted colon cancer patients, found the antidepressant made little difference to their survival.
The first swot found that adding Avastin to standard chemotherapy (carboplatin and paclitaxel) and continuing with "maintenance" Avastin after chemo as a matter of fact slowed the time-to-disease recurrence in women with advanced ovarian cancer. Avastin is an anti-angiogenic drug, gist it interferes with a tumor's blood supply. "This is the first molecular-targeted and opening anti-angiogenesis therapy to demonstrate benefit in this population and, combined with chemotherapy followed by Avastin maintenance, should be considered as one law option for women with this disease," said lead researcher Dr Robert A Burger, governor of the Women's Cancer Center at Fox Chase Cancer Center in Philadelphia.
So "This is a unusual potential treatment paradigm for stage 3 and 4 ovarian cancer," added Dr Jennifer Obel, an attending medical doctor at Northshore University Health System and arbiter of a Sunday news conference at which these results were presented. The phase 3 think over involved almost 1,900 women with stage 3 and stage 4 ovarian cancer. Those who received canon chemotherapy plus Avastin, and then maintenance Avastin, for up to 10 months lived just over 14 months without their complaint progressing compared with about 10 months for those receiving example chemotherapy alone.
Those who received chemo plus Avastin but no maintenance drug lived without a recurrence for 11,3 months, a diversity not considered statistically significant. "I'm cautiously optimistic about this data. It utterly shows that those who had maintenance Avastin had improved profession-free survival," said Dr Robert Morgan, co-director of the gynecologic oncology program at City of Hope Cancer Center in Duarte, Calif. "I ruminate we have to heels for longer term outcomes before we make particular conclusions. It's too early for overall survival benefit data".
However, he pointed out, a four-month conversion for progression-free survival is "substantial". Doctors are already using Avastin off-label widely to treat ovarian cancer, he said, although it is not yet approved for this use. It has been shown to be more effective in this cancer than in many cancers for which it is approved, Morgan noted.
Wednesday 29 January 2014
Reduced Levels Of Smoking Among Adolescents Has Stopped
Reduced Levels Of Smoking Among Adolescents Has Stopped.
The deterioration in the thousand of US high school students who smoke has slowed significantly, following striking drops starting in the late 1990s, according to a new federal report. Twenty percent of drugged school students still smoke, making it impossible to reach the 2010 national goal of reducing cigarette use amongst teens to 16 percent or less, the US Centers for Disease Control and Prevention reported. "The percentage of change started slowing in 2003, and in some groups of students has thoroughly stopped and is almost not declining at all," noted lead study author Terry F Pechacek, associated director for science at the CDC's Office on Smoking and Health.
And "The only arrange in which we are seeing a decline is in African-American females," he added. Part of the problem, Pechacek said, is that "we have enchanted our eye off the issue. Sometimes, we get complacent with our success and move on to other things".
Also, states have significantly prepare their budgets for tobacco education and cessation programs, Pechacek said. And the tobacco trade continues to aggressively target teenagers, he said, adding, "The industry has been left with the only expression out there with their $12 billion campaign".
Pechacek said there needs to be renewed emphasis on getting teens not to smoke. "We've got a recent opportunity with the FDA legislation which gives the agency oversight over the tobacco industry and the ability it gives the community to do more about restricting advertising, broadside and availability of tobacco products," he said.
That effort needs to be combined with stronger anti-smoking programs, including smoke-free laws and increases in cigarette taxes, Pechacek said. "The talent to seal off the inflow of new smokers is critical," he said. "The happening that we have had a stall has dramatic implications for the future. Millions of more youth are going to become addicted and one in three of them are universal to die prematurely".
The deterioration in the thousand of US high school students who smoke has slowed significantly, following striking drops starting in the late 1990s, according to a new federal report. Twenty percent of drugged school students still smoke, making it impossible to reach the 2010 national goal of reducing cigarette use amongst teens to 16 percent or less, the US Centers for Disease Control and Prevention reported. "The percentage of change started slowing in 2003, and in some groups of students has thoroughly stopped and is almost not declining at all," noted lead study author Terry F Pechacek, associated director for science at the CDC's Office on Smoking and Health.
And "The only arrange in which we are seeing a decline is in African-American females," he added. Part of the problem, Pechacek said, is that "we have enchanted our eye off the issue. Sometimes, we get complacent with our success and move on to other things".
Also, states have significantly prepare their budgets for tobacco education and cessation programs, Pechacek said. And the tobacco trade continues to aggressively target teenagers, he said, adding, "The industry has been left with the only expression out there with their $12 billion campaign".
Pechacek said there needs to be renewed emphasis on getting teens not to smoke. "We've got a recent opportunity with the FDA legislation which gives the agency oversight over the tobacco industry and the ability it gives the community to do more about restricting advertising, broadside and availability of tobacco products," he said.
That effort needs to be combined with stronger anti-smoking programs, including smoke-free laws and increases in cigarette taxes, Pechacek said. "The talent to seal off the inflow of new smokers is critical," he said. "The happening that we have had a stall has dramatic implications for the future. Millions of more youth are going to become addicted and one in three of them are universal to die prematurely".
Sunday 26 January 2014
Deer Ticks Carry Lyme Disease Germs
Deer Ticks Carry Lyme Disease Germs.
People who go outdoors in several regions of the United States may have something else to agonize about. Scientists arrive that there's another troublesome bacterium hiding in the deer tick that already harbors the Lyme disease bacterium. There are indications that the virus infects a few thousand Americans a year, potentially causing flu-like symptoms such as fever. In one newly reported case, a piece with existing medical problems appeared to have brain tumescence and dementia caused by an infection.
It is not clear, however, how serious of a threat may be posed by the germ. For the moment, Lyme blight appears to be much more prevalent. And four other germs that affect humans skulk in deer ticks. Still, scientists say the germ is cause for concern.
And "This would not be commonly picked up by any of the aware tests for Lyme disease," said Victor Berardi, co-author of one of two reports about the basis in the Jan 17, 2013 issue of the New England Journal of Medicine. The bacterium in pump is Borrelia miyamotoi and is found on deer ticks (also known as blacklegged ticks) in parts of the outback where Lyme disease is prevalent.
In 2011, Russian researchers reported that populace there were infected by the bacterium, and the new reports have found that it has infected people in the United States as well. "We've known about this bacterium for a big time - at least 10 years," said Sam Telford III, a professor of transmissible disease at Tufts University in Medford, Mass, who co-authored the account with Berardi.
People who go outdoors in several regions of the United States may have something else to agonize about. Scientists arrive that there's another troublesome bacterium hiding in the deer tick that already harbors the Lyme disease bacterium. There are indications that the virus infects a few thousand Americans a year, potentially causing flu-like symptoms such as fever. In one newly reported case, a piece with existing medical problems appeared to have brain tumescence and dementia caused by an infection.
It is not clear, however, how serious of a threat may be posed by the germ. For the moment, Lyme blight appears to be much more prevalent. And four other germs that affect humans skulk in deer ticks. Still, scientists say the germ is cause for concern.
And "This would not be commonly picked up by any of the aware tests for Lyme disease," said Victor Berardi, co-author of one of two reports about the basis in the Jan 17, 2013 issue of the New England Journal of Medicine. The bacterium in pump is Borrelia miyamotoi and is found on deer ticks (also known as blacklegged ticks) in parts of the outback where Lyme disease is prevalent.
In 2011, Russian researchers reported that populace there were infected by the bacterium, and the new reports have found that it has infected people in the United States as well. "We've known about this bacterium for a big time - at least 10 years," said Sam Telford III, a professor of transmissible disease at Tufts University in Medford, Mass, who co-authored the account with Berardi.
Thursday 23 January 2014
To Maintain The Health Of The Brain Needs Vitamins D And E
To Maintain The Health Of The Brain Needs Vitamins D And E.
Three unripe studies suggest that vitamins D and E might labourer memorialize our minds sharper, aid in warding off dementia, and even offer some protection against Parkinson's disease, although much more fact-finding is needed to confirm the findings. In one trial, British researchers tied smutty levels of vitamin D to higher odds of developing dementia, while a Dutch study found that commoners with diets rich in vitamin E had a lower risk of developing dementia, including Alzheimer's disease.
Finally, a cram released by Finnish researchers linked high blood levels of vitamin D to a debase risk of Parkinson's disease. In the first report, published in the July 12 spring of the Archives of Internal Medicine, a research team led by David J Llewellyn of the University of Exeter in the United Kingdom found that amidst 858 older adults, those with ignoble levels of vitamin D were more likely to develop dementia.
In fact, people who had blood levels of vitamin D soften than 25 nanomoles per liter were 60 percent more inclined to to develop substantial declines overall in thinking, learning and memory over the six years of the study. In addition, they were 31 percent more in all probability to have lower scores in the test measuring "executive function" than those with adequate vitamin D levels, while levels of attention remained unaffected, the researchers found. "Executive function" is a set of high-level cognitive abilities that better people organize, prioritize, modify to change and plan for the future.
And "The association remained significant after adjustment for a wide range of likely factors , and when analyses were restricted to elderly subjects who were non-demented at baseline," Llewellyn's line-up wrote. The possible role of vitamin D in preventing other illnesses has been investigated by other researchers, but one excellent cautioned that the evidence for taking vitamin D supplements is still unproven.
So "There is currently completely a lot of enthusiasm for vitamin D supplementation, of both individuals and populations, in the belief that it will reduce the weigh down of many diseases," said Dr Andrew Grey, an associate professor of medicine at the University of Auckland in New Zealand and co-author of an position statement in the July 12 issue of the Archives of Internal Medicine. "This fervour is predicated upon data from observational studies - which are subject to confounding, and are hypothesis-generating rather than hypothesis-testing - rather than randomized controlled trials," Grey said. "Calls for widespread vitamin D supplementation are unripe on the essence of current evidence".
In another report involving vitamin D and perspicacity health, researchers led by Paul Knekt and colleagues at the National Institute for Health and Welfare in Helsinki, Finland, found that ancestors with higher serum levels of vitamin D appear to have a degrade risk of developing Parkinson's disease. Their report was published in the July issue of the Archives of Neurology.
For the study, Knekt and his gang collected data on almost 3200 Finnish men and women superannuated 50 to 79 who did not have Parkinson's disease when the study began. Over 29 years of follow-up, 50 mobile vulgus developed Parkinson's disease. The researchers calculated that rank and file with the highest levels of vitamin D had a 67 percent lower risk of developing Parkinson's infection compared with those with the lowest levels of vitamin D.
Three unripe studies suggest that vitamins D and E might labourer memorialize our minds sharper, aid in warding off dementia, and even offer some protection against Parkinson's disease, although much more fact-finding is needed to confirm the findings. In one trial, British researchers tied smutty levels of vitamin D to higher odds of developing dementia, while a Dutch study found that commoners with diets rich in vitamin E had a lower risk of developing dementia, including Alzheimer's disease.
Finally, a cram released by Finnish researchers linked high blood levels of vitamin D to a debase risk of Parkinson's disease. In the first report, published in the July 12 spring of the Archives of Internal Medicine, a research team led by David J Llewellyn of the University of Exeter in the United Kingdom found that amidst 858 older adults, those with ignoble levels of vitamin D were more likely to develop dementia.
In fact, people who had blood levels of vitamin D soften than 25 nanomoles per liter were 60 percent more inclined to to develop substantial declines overall in thinking, learning and memory over the six years of the study. In addition, they were 31 percent more in all probability to have lower scores in the test measuring "executive function" than those with adequate vitamin D levels, while levels of attention remained unaffected, the researchers found. "Executive function" is a set of high-level cognitive abilities that better people organize, prioritize, modify to change and plan for the future.
And "The association remained significant after adjustment for a wide range of likely factors , and when analyses were restricted to elderly subjects who were non-demented at baseline," Llewellyn's line-up wrote. The possible role of vitamin D in preventing other illnesses has been investigated by other researchers, but one excellent cautioned that the evidence for taking vitamin D supplements is still unproven.
So "There is currently completely a lot of enthusiasm for vitamin D supplementation, of both individuals and populations, in the belief that it will reduce the weigh down of many diseases," said Dr Andrew Grey, an associate professor of medicine at the University of Auckland in New Zealand and co-author of an position statement in the July 12 issue of the Archives of Internal Medicine. "This fervour is predicated upon data from observational studies - which are subject to confounding, and are hypothesis-generating rather than hypothesis-testing - rather than randomized controlled trials," Grey said. "Calls for widespread vitamin D supplementation are unripe on the essence of current evidence".
In another report involving vitamin D and perspicacity health, researchers led by Paul Knekt and colleagues at the National Institute for Health and Welfare in Helsinki, Finland, found that ancestors with higher serum levels of vitamin D appear to have a degrade risk of developing Parkinson's disease. Their report was published in the July issue of the Archives of Neurology.
For the study, Knekt and his gang collected data on almost 3200 Finnish men and women superannuated 50 to 79 who did not have Parkinson's disease when the study began. Over 29 years of follow-up, 50 mobile vulgus developed Parkinson's disease. The researchers calculated that rank and file with the highest levels of vitamin D had a 67 percent lower risk of developing Parkinson's infection compared with those with the lowest levels of vitamin D.
Monday 20 January 2014
Allergic Risk When Eating Peanuts During Pregnancy
Allergic Risk When Eating Peanuts During Pregnancy.
Women who tie on the nosebag peanuts during pregnancy may be putting their babies at increased gamble for peanut allergy, a new workroom suggests. US researchers looked at 503 infants, aged 3 months to 15 months, with suspected egg or bleed allergies, or with the skin disorder eczema and positive allergy tests to drain or egg. These factors are associated with increased risk of peanut allergy, but none of the infants in the studio had been diagnosed with peanut allergy.
Blood tests revealed that 140 of the infants had persistent sensitivity to peanuts. Mothers' consumption of peanuts during pregnancy was a strong predictor of peanut receptibility in the infants, the researchers reported in the Nov 1, 2010 issue of the Journal of Allergy and Clinical Immunology. "Researchers in just out years have been uncertain about the role of peanut consumption during pregnancy on the hazard of peanut allergy in infants.
While our study does not definitively indicate that pregnant women should not eat peanut products during pregnancy, it highlights the sine qua non for further research in order to make recommendations about dietary restrictions," contemplation leader Dr Scott H Sicherer, a professor of pediatrics at Jaffe Food Allergy Institute at the Mount Sinai School of Medicine in New York City, said in a paper news programme release.
Sicherer and his colleagues recommended controlled, interventional studies to further explore their findings. "Peanut allergy is serious, in the main persistent, potentially fatal, and appears to be increasing in prevalence," Sicherer said.
Peanuts are surrounded by the most common allergy-causing foods. But because a peanut allergy is less probably to be outgrown than allergies to other foods, it becomes more common among older kids and adults. It's odds-on that more Americans are allergic to peanuts than any other food.
Women who tie on the nosebag peanuts during pregnancy may be putting their babies at increased gamble for peanut allergy, a new workroom suggests. US researchers looked at 503 infants, aged 3 months to 15 months, with suspected egg or bleed allergies, or with the skin disorder eczema and positive allergy tests to drain or egg. These factors are associated with increased risk of peanut allergy, but none of the infants in the studio had been diagnosed with peanut allergy.
Blood tests revealed that 140 of the infants had persistent sensitivity to peanuts. Mothers' consumption of peanuts during pregnancy was a strong predictor of peanut receptibility in the infants, the researchers reported in the Nov 1, 2010 issue of the Journal of Allergy and Clinical Immunology. "Researchers in just out years have been uncertain about the role of peanut consumption during pregnancy on the hazard of peanut allergy in infants.
While our study does not definitively indicate that pregnant women should not eat peanut products during pregnancy, it highlights the sine qua non for further research in order to make recommendations about dietary restrictions," contemplation leader Dr Scott H Sicherer, a professor of pediatrics at Jaffe Food Allergy Institute at the Mount Sinai School of Medicine in New York City, said in a paper news programme release.
Sicherer and his colleagues recommended controlled, interventional studies to further explore their findings. "Peanut allergy is serious, in the main persistent, potentially fatal, and appears to be increasing in prevalence," Sicherer said.
Peanuts are surrounded by the most common allergy-causing foods. But because a peanut allergy is less probably to be outgrown than allergies to other foods, it becomes more common among older kids and adults. It's odds-on that more Americans are allergic to peanuts than any other food.
Saturday 18 January 2014
New Drug To Treat Cystic Fibrosis
New Drug To Treat Cystic Fibrosis.
A supplemental hallucinogen focused on the underlying cause of cystic fibrosis is showing promise in Phase II clinical trials, rejuvenated research shows. If eventually approved by the US Food and Drug Administration, the painkiller known as VX-770 would mark the first treatment that gets at what goes wrong in the lungs of masses with cystic fibrosis, rather than just the symptoms. Only 4 to 5 percent of cystic fibrosis patients have the noteworthy genetic variant that the drug is being studied to treat, according to the study.
But Robert Beall, president and CEO of the Cystic Fibrosis Foundation, said VX-770 is only the in the first place in a new class of drugs, some of which are already in the pipeline, that may duty in a similar way in people with other cystic fibrosis-linked gene variants. "There has never been such a detect of hope and optimism in the cystic fibrosis community," Beall said. "This is the prime time there's been a treatment for the basic defect in cystic fibrosis. If we can treat it early, c we won't have all the infections that destroy the lungs and eventually takes people's lives away".
The investigation appears in the Nov 18, 2010 issue of the New England Journal of Medicine. Cystic fibrosis is a progressive, inherited c murrain affecting about 30000 US children and adults. It is caused by a want in the CF gene, which produces the CFTR (cystic fibrosis transmembrane conductance regulator) protein, which is high-ranking in the transport of salt and fluids in the cells of the lungs and digestive tract.
In in good cells, when chloride moves out of cells, water follows, keeping the mucus around the cubicle hydrated. However, in people with the faulty CFTR protein, the chloride channels don't handiwork properly. Chloride and water in the cells of the lungs stay trapped inside the cell, causing the mucus to become thick, ticklish and dehydrated.
Overtime, the abnormal mucus builds up in the lungs and in the pancreas, which helps to tell down and absorb food, causing both breathing and digestive problems. In the lungs, the heaping up of the mucus leaves people prone to serious, hard-to-treat and recurrent infections. Overtime, the repeated infections cancel the lungs. The average life expectancy for a person with cystic fibrosis is about 37, according to the Cystic Fibrosis Foundation.
A supplemental hallucinogen focused on the underlying cause of cystic fibrosis is showing promise in Phase II clinical trials, rejuvenated research shows. If eventually approved by the US Food and Drug Administration, the painkiller known as VX-770 would mark the first treatment that gets at what goes wrong in the lungs of masses with cystic fibrosis, rather than just the symptoms. Only 4 to 5 percent of cystic fibrosis patients have the noteworthy genetic variant that the drug is being studied to treat, according to the study.
But Robert Beall, president and CEO of the Cystic Fibrosis Foundation, said VX-770 is only the in the first place in a new class of drugs, some of which are already in the pipeline, that may duty in a similar way in people with other cystic fibrosis-linked gene variants. "There has never been such a detect of hope and optimism in the cystic fibrosis community," Beall said. "This is the prime time there's been a treatment for the basic defect in cystic fibrosis. If we can treat it early, c we won't have all the infections that destroy the lungs and eventually takes people's lives away".
The investigation appears in the Nov 18, 2010 issue of the New England Journal of Medicine. Cystic fibrosis is a progressive, inherited c murrain affecting about 30000 US children and adults. It is caused by a want in the CF gene, which produces the CFTR (cystic fibrosis transmembrane conductance regulator) protein, which is high-ranking in the transport of salt and fluids in the cells of the lungs and digestive tract.
In in good cells, when chloride moves out of cells, water follows, keeping the mucus around the cubicle hydrated. However, in people with the faulty CFTR protein, the chloride channels don't handiwork properly. Chloride and water in the cells of the lungs stay trapped inside the cell, causing the mucus to become thick, ticklish and dehydrated.
Overtime, the abnormal mucus builds up in the lungs and in the pancreas, which helps to tell down and absorb food, causing both breathing and digestive problems. In the lungs, the heaping up of the mucus leaves people prone to serious, hard-to-treat and recurrent infections. Overtime, the repeated infections cancel the lungs. The average life expectancy for a person with cystic fibrosis is about 37, according to the Cystic Fibrosis Foundation.
Thursday 16 January 2014
Ways To Treat Patients With Type 2 Diabetes To Heart Disease
Ways To Treat Patients With Type 2 Diabetes To Heart Disease.
Using surgical procedures to air clogged arteries in joining to regulatory drug therapy seems to work better at maintaining good blood flow in diabetics with feeling disease, new research finds. The analysis, being presented Tuesday at the American Heart Association's annual assembly in Chicago, is part of a larger randomized clinical trial deciphering how best to critique type 2 diabetics with heart disease. In that study, the US government-funded BARI 2D, all participants took cholesterol-lowering medications and blood demand drugs. They were then were randomized either to carry on on drugs alone or to undergo a revascularization procedure - either bypass surgery or angioplasty.
The beginning findings showed that patients fared equally well with either treatment strategy. But this more up to date analysis took things a step further and found that there did, in fact, appear to be an added benefit from artery-opening procedures by the end of one year. More than 1500 patients who had participated in the individualist trial underwent an imaging approach called stress myocardial perfusion SPECT or MPS, which were then analyzed in this study.
And "At one year, interestingly, we slogan that patients who were randomized to revascularization had significantly less severe and less extensive and less severe myocardial perfusion blood go abnormalities," said study author Leslee J Shaw, professor of cure-all at Emory University School of Medicine in Atlanta. Shaw reported ties with divergent pharmaceutical and related companies.
Using surgical procedures to air clogged arteries in joining to regulatory drug therapy seems to work better at maintaining good blood flow in diabetics with feeling disease, new research finds. The analysis, being presented Tuesday at the American Heart Association's annual assembly in Chicago, is part of a larger randomized clinical trial deciphering how best to critique type 2 diabetics with heart disease. In that study, the US government-funded BARI 2D, all participants took cholesterol-lowering medications and blood demand drugs. They were then were randomized either to carry on on drugs alone or to undergo a revascularization procedure - either bypass surgery or angioplasty.
The beginning findings showed that patients fared equally well with either treatment strategy. But this more up to date analysis took things a step further and found that there did, in fact, appear to be an added benefit from artery-opening procedures by the end of one year. More than 1500 patients who had participated in the individualist trial underwent an imaging approach called stress myocardial perfusion SPECT or MPS, which were then analyzed in this study.
And "At one year, interestingly, we slogan that patients who were randomized to revascularization had significantly less severe and less extensive and less severe myocardial perfusion blood go abnormalities," said study author Leslee J Shaw, professor of cure-all at Emory University School of Medicine in Atlanta. Shaw reported ties with divergent pharmaceutical and related companies.
Tuesday 14 January 2014
Halving Appeal For Emergency Aid For Children Under Two Years
Halving Appeal For Emergency Aid For Children Under Two Years.
Three years after nonprescription infant dead medicines were bewitched off the market, predicament rooms treat less than half as many children under 2 for overdoses and other adverse reactions to the drugs, a inexperienced US government study shows. A voluntary withdrawal of over-the-counter cough and freezing medicines for children aged 2 and under took effect in October 2007 because of concerns about concealed harm and lack of effectiveness. The following year, the withdrawal was extended to medications intended for 4-year-olds, the researchers say.
And "I dream it's good that these products were withdrawn, but it's not accepted to take care of the entire problem," said lead researcher Dr Daniel S Budnitz, of the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention (CDC). Since more than two-thirds of these exigency bailiwick visits were the result of young children getting into medicines on their own, problems are seemly to continue, he said. The report is published online Nov 22, 2010 in Pediatrics.
For the study, Budnitz's rig tracked visits to US hospital danger departments by children under 12 who were treated for adverse events tied to over-the-counter cold medications in the 14 months before and after the withdrawal. Although the whole number of visits remained the same before and after the withdrawal, amidst children under 2 these visits dropped from 2,790 to 1,248 - more than 50 percent, the researchers found.
But, as with crisis department visits before the withdrawal, 75 percent of cases involving the flu medications resulted from children taking these drugs while unsupervised. Whether these emergency department visits concerned cough and cold medicines for children or adults isn't known, Budnitz said.
Three years after nonprescription infant dead medicines were bewitched off the market, predicament rooms treat less than half as many children under 2 for overdoses and other adverse reactions to the drugs, a inexperienced US government study shows. A voluntary withdrawal of over-the-counter cough and freezing medicines for children aged 2 and under took effect in October 2007 because of concerns about concealed harm and lack of effectiveness. The following year, the withdrawal was extended to medications intended for 4-year-olds, the researchers say.
And "I dream it's good that these products were withdrawn, but it's not accepted to take care of the entire problem," said lead researcher Dr Daniel S Budnitz, of the Division of Healthcare Quality Promotion at the Centers for Disease Control and Prevention (CDC). Since more than two-thirds of these exigency bailiwick visits were the result of young children getting into medicines on their own, problems are seemly to continue, he said. The report is published online Nov 22, 2010 in Pediatrics.
For the study, Budnitz's rig tracked visits to US hospital danger departments by children under 12 who were treated for adverse events tied to over-the-counter cold medications in the 14 months before and after the withdrawal. Although the whole number of visits remained the same before and after the withdrawal, amidst children under 2 these visits dropped from 2,790 to 1,248 - more than 50 percent, the researchers found.
But, as with crisis department visits before the withdrawal, 75 percent of cases involving the flu medications resulted from children taking these drugs while unsupervised. Whether these emergency department visits concerned cough and cold medicines for children or adults isn't known, Budnitz said.
Saturday 11 January 2014
Influenza Vaccine In The USA Is Not Enough
Influenza Vaccine In The USA Is Not Enough.
Sporadic shortages of both the flu vaccine and the flu remedying Tamiflu are being reported, as this year's burning flu opportunity continues, according to a top US health official. "We have received reports that some consumers have found splodge shortages of the vaccine," Dr Margaret Hamburg, commissioner of the US Food and Drug Administration, said on her blog on the agency's website. Hamburg said that the instrumentality is "monitoring this location and will update you at our website and at flu dot gov".
So far, more than 128 million doses of flu vaccine have been distributed, Hamburg said, but not all the doses have been administered to man yet. She said that proletariat who already have the flu may also be experiencing local shortages of Tamiflu, a drug that can help treat influenza. "We do prophesy intermittent, temporary shortages of the oral suspension form of Tamiflu - the bright version often prescribed for children - for the remainder of the flu season.
However, FDA is working with the industrialist to increase supply," she said. Hamburg also noted that "FDA-approved instructions on the label specify directions for pharmacists on how to compound a liquid form of Tamiflu from Tamiflu capsules". Flu mature typically peaks in January or February but can extend as late as May.
Sporadic shortages of both the flu vaccine and the flu remedying Tamiflu are being reported, as this year's burning flu opportunity continues, according to a top US health official. "We have received reports that some consumers have found splodge shortages of the vaccine," Dr Margaret Hamburg, commissioner of the US Food and Drug Administration, said on her blog on the agency's website. Hamburg said that the instrumentality is "monitoring this location and will update you at our website and at flu dot gov".
So far, more than 128 million doses of flu vaccine have been distributed, Hamburg said, but not all the doses have been administered to man yet. She said that proletariat who already have the flu may also be experiencing local shortages of Tamiflu, a drug that can help treat influenza. "We do prophesy intermittent, temporary shortages of the oral suspension form of Tamiflu - the bright version often prescribed for children - for the remainder of the flu season.
However, FDA is working with the industrialist to increase supply," she said. Hamburg also noted that "FDA-approved instructions on the label specify directions for pharmacists on how to compound a liquid form of Tamiflu from Tamiflu capsules". Flu mature typically peaks in January or February but can extend as late as May.
Subscribe to:
Posts (Atom)